Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of anti-diabetes drugs with proven efficiency in the treatment of diabetes, which have recently shown striking results as weight loss medications, such that it is conceivable that long term use might be useful to prevent cancers associated with obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.